Zhejiang Haichang Biotech Co., Ltd.
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.
Inclusion Criteria: * ≥18 years of age on the day of signing informed consent, male or female. * Voluntarily agree to provide signed informed consent and are willing and able to comply with all aspects of the protocol. * Histologically or cytologically confirmed diagnosis of HCC, or clinical diagnosis of HCC as per AASLD criteria. * BCLC Stage C or BCLC Stage B with bilobar involvement and infiltrative nature that is only suitable for systemic anti-tumor therapy, and not suitable for any curative surgeries, liver transplantation, or local therapy (BCLC Classification see Appendix 6, Section 1…
WGI-0301 at Maximum Tolerated Dose (MTD)
WGI-0301 at dose level below Maximum Tolerated Dose (MTD-1)
Lenvatinib for patients with body weight of \<60 kg: 8 mg orally daily, for patients with body weight ≥60 kg: 12 mg orally daily
Arctuva estimate
Verify or correct the compensation shown for this listing.